- Shares of GTx (GTXI +9%) are trading notably higher.
- The company said today it will present top line results from POWER1 and POWER2 at the European Cancer Congress.
- The Phase 3 trials evaluated enobosarm as a treatment for muscle wasting in patients with non-small cell lung cancer.
- It's perhaps worth noting here that these trials did not meet their pre-specified criteria, news that, when released back on August 19, sent GTXI tumbling some 65%.
GTx rallies as company set to present data from trial misses at conference
From other sites
at Zacks.com (Mar 5, 2015)
at MarketWatch.com (May 8, 2012)
at MarketWatch.com (Feb 21, 2012)
at MarketWatch.com (Jan 30, 2012)
at MarketWatch.com (Jun 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs